# Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy Subjects

> **NCT06423261** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Zhejiang Echon Biopharm Limited** · enrollment: 100 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GB002 Recombinant Peptide Inhalation Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06423261
- **Lead sponsor:** Zhejiang Echon Biopharm Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-24
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-07-29
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06423261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06423261, "Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06423261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*